Royalty Pharma plc (RPRX) Down 6.0% — Should I Scale Back Here?
Royalty Pharma plc (RPRX) endured a punishing session this Tuesday, dropping 6.01% and shedding $3.84 to close at $60.12 on the NASDAQ. The decline is particularly sharp in context: just four days earlier, on September 4, the stock had touched a 52-week high of $64.38 — meaning shares have now reversed course and sit roughly 6.6% below that peak after what briefly looked like a breakout. The swift round-trip underscores how quickly sentiment can shift when a key pipeline asset stumbles.
Volume came in at approximately 2.97 million shares, running below the 90-day average of roughly 3.40 million. The lighter-than-typical turnover did little to cushion the decline, suggesting the selling was deliberate rather than panic-driven — measured repositioning rather than a broad-based flush.
Why Royalty Pharma plc Price is Moving Lower
The catalyst is specific and damaging: a delayed market reaction to Novartis' (NVS) September 4 announcement that pelacarsen failed its Phase 3 HORIZON trial. The trial, designed to evaluate pelacarsen in patients with elevated Lp(a) and established cardiovascular disease, did not meet its primary endpoint of reducing a composite of cardiovascular death, non-fatal heart attack, non-fatal stroke, and urgent coronary revascularization versus placebo. Because pelacarsen is a royalty-linked asset for Royalty Pharma, the failure materially reduces the expected stream of future milestone and royalty payments tied to the drug. The news broke before the weekend, and with U.S. markets closed on Monday, Tuesday marked the first full session for investors to price in the damage — and they did so swiftly, sending shares down roughly 6.0% to close near $60.11.
What makes the situation harder to navigate is the absence of granular data. Novartis has not disclosed the hazard ratio, event counts, or p-value from the HORIZON trial, leaving investors with no statistical framework to assess whether pelacarsen retains any residual commercial potential or whether a narrower label might salvage part of the asset's value. That information vacuum is its own risk — it prevents a clean write-down of expectations and keeps uncertainty elevated. For a business model built around probabilistic royalty streams across a diversified portfolio, a high-profile Phase 3 failure of this nature isn't just a one-time write-off; it raises questions about the pipeline assumptions underpinning current valuation.
The broader fundamental picture offers some counterbalance, though it doesn't fully absorb the blow. In its most recent earnings report on August 5, RPRX posted EPS of $1.32 against a $1.27 consensus estimate, a $0.05 beat, while royalty receipts rose 14% year over year to $768 million and adjusted EBITDA climbed 16% to $736 million. Revenue of $674 million missed the $758.93 million estimate but still grew 16% from $579 million a year earlier. The offsetting concern — net income attributable to Royalty Pharma fell 44% to $18 million — was already a point of scrutiny before the pelacarsen setback added a new layer of uncertainty about the durability of future cash flows.
What is the Royalty Pharma plc Rating - Should I Sell?
Weiss Ratings assigns RPRX a B- rating. Current recommendation is Buy.
The B- rating reflects a business that earns its marks across several key dimensions without quite reaching the top tier. Revenue growth of 16.50% and a profit margin of 32.13% together earn the Good Growth Index — numbers that demonstrate Royalty Pharma's model of acquiring royalty interests in approved and late-stage medicines continues to generate real income, even as individual assets like pelacarsen periodically disappoint. ROE of 14.00% supports the Good Efficiency Index — a reasonable return for a capital-allocator operating in the capital-intensive world of pharmaceutical royalty financing, where deploying large sums against long-dated, probabilistic cash flows is the core business challenge. The Excellent Solvency Index is perhaps the most reassuring data point given today's news: it indicates the balance sheet can absorb setbacks without threatening the company's financial footing. The Good Total Return Index and Good Volatility Index round out a profile that, while not exceptional, reflects a business managing risk with reasonable discipline.
Where the rating stops short of a B is worth acknowledging honestly. The B- sits at the lower boundary of the Buy range, and today's events illustrate exactly why — a single late-stage trial failure can materially reprice a royalty stream and compress near-term upside. Investors weighing whether to hold or add here should recognize that the B- is not the same as a B: the modifier reflects real differentiation in the risk profile, and the pelacarsen outcome may put additional pressure on the sub-indices in future rating updates if follow-on royalty pipeline losses mount.
Within the Health Care sector, Royalty Pharma is on equal footing with AbbVie Inc. (ABBV, B-) and Vertex Pharmaceuticals Incorporated (VRTX, B-), while ranking behind Eli Lilly and Company (LLY, B), Johnson & Johnson (JNJ, B), and Amgen Inc. (AMGN, B). That peer comparison provides useful context: RPRX belongs to the second tier of Buy-rated names in the sector, which is worth keeping in mind as investors assess how much of today's decline represents opportunity versus a more persistent re-rating of the royalty portfolio.
About Royalty Pharma plc
Royalty Pharma plc (RPRX) is a Health Care company that occupies a structurally distinct position compared to traditional drug developers. Rather than conducting its own clinical research or manufacturing medicines, Royalty Pharma acquires royalty interests in commercial and late-stage biopharmaceutical products — essentially purchasing the right to receive a percentage of future product revenues in exchange for upfront capital. This model gives the company broad exposure to some of the most commercially significant medicines in the world without bearing the full operational burden of bringing a drug to market.
The company's royalty portfolio spans a wide range of therapeutic areas, including rare diseases, oncology, neuroscience, infectious disease, hematology, and cardiovascular conditions. Key royalty-generating assets include interests in treatments like cystic fibrosis therapies, cancer medicines, and immunology drugs developed and marketed by major pharmaceutical companies. By financing the development and commercialization needs of biopharmaceutical innovators — providing capital that allows companies to advance their pipelines — Royalty Pharma creates a pipeline of long-duration cash flows that is difficult to replicate through traditional equity or debt financing alone.
Royalty Pharma's competitive advantages stem from its scale, relationships, and institutional expertise in evaluating complex probabilistic royalty assets. As the largest buyer of biopharmaceutical royalties in the world, the company can access deal flow and diligence resources unavailable to smaller participants. Its diversified portfolio — spanning dozens of royalty interests across approved products and late-stage programs — provides structural resilience, even when individual assets like pelacarsen fall short. The business model's inherent leverage to pharmaceutical innovation cycles, combined with a disciplined approach to capital deployment, positions Royalty Pharma as a distinctive vehicle for Health Care exposure.
Investor Outlook
Royalty Pharma plc (RPRX) carries a Weiss B- rating with a Buy recommendation, but today's 6.01% decline on the heels of the pelacarsen Phase 3 failure serves as a clear reminder of the pipeline risks embedded in a royalty-based model. In the near term, investors should watch for any additional disclosure from Novartis on the HORIZON trial data and monitor whether the company updates its guidance or royalty receipt projections in response. See full rankings of all B--rated Health Care stocks inside the Weiss Stock Screener.
--